Please assess the completion status of the following clinical trial:

Trial Title: Hydroxychloroquine for the Treatment of Mild COVID-19 Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be ≥18 years at the time of signing the informed consent~* Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures~* Able to adhere to the study visit schedule and other protocol requirements~* Mild COVID-19 with outpatient management as decided by the treating physician~* Early warning score for 2019-nCoV infected patients ≤ 5~* Females of childbearing potential (FCBP1) must agree~* to utilize two reliable forms of contraception simultaneously or practice complete abstinence from heterosexual contact for at least 28 days before starting study drug, while participating in the study (including dose interruptions), and for at least 28 days after study treatment discontinuation and must agree to regular pregnancy testing during this timeframe~* to abstain from breastfeeding during study participation and 28 days after study drug discontinuation~* All subjects must agree to refrain from donating blood while on study drug and for 28 days after discontinuation from this study treatment~* All subjects must agree not to share medication~Exclusion Criteria:~* Requirement for oxygen administration~* Shortness of breath in resting position~* Creatinin \> 2.0 mg/dl~* Women during pregnancy and lactation~* Participation in other clinical trials or observation period of competing trials~* Active or clinically significant cardiac disease including congestive heart failure (New York Heart Association Class III or higher)~* History or current evidence of clinically significant cardiac arrhythmia except atrial fibrillation or paroxysmal supraventricular tachycardia~* Use of concomitant medications that prolong the QT/QTc interval~* Physician decision that involvement in the study is not in the patient´s best interest

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Hydroxychloroquine (Type: EXPERIMENTAL): Hydroxychloroquine 600mg daily for 7 days
- Placebo (Type: PLACEBO_COMPARATOR): Equivalent number of placebo capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).